Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tech Transfer Roundup: Sanofi Gets IP For Multiple Myeloma From Memorial Sloan Kettering

Executive Summary

The intellectual property, also held by Eureka, may offer a new pathway for treating relapsed MM patients. Sorrento inks cancer partnerships with Karolinska Institutet and Mayo Clinic.

You may also be interested in...



Finance Watch: Exo Raises $78m To Advance Exosite-Targeting Small Molecules

Also, Atlas Venture and Advent France Biotechnology raise new venture capital funds, Corium secures $235m in debt to commercialize ADHD drug and CBMG leads recent VC financings with $120m series A round.

BridgeBio’s Hub-And-Spoke Model: An Interview With Cameron Turtle

Since raising $135m in 2017 to address rare, monogenic diseases, BridgeBio has launched or purchased 17 companies and built a pipeline of 30-plus candidates. Scrip checked in as the company nears commercialization.

Tech Transfer Roundup: Oncology Deals Focus On CAR-T Innovations, ADCs, DNA Damage Response

Cancer deals involve City of Hope/Chimeric, CARISMA/NYU, Sorrento/Mayo Clinic, Rain/Drexel, Diaprost/Memorial Sloan Kettering, Alkido/University of Kentucky. Plus, research collaborations in brief.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC144687

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel